timolol ophthalmic solution 0.5%

DRUG2 trials

Sponsors

Allergan, Santen Pharmaceutical Co., Ltd.

Conditions

Glaucoma, Open-AngleOcular HypertensionOpen Angle Glaucoma

Phase 1

Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

CompletedNCT01215786

AllerganGlaucoma, Open-Angle, Ocular Hypertension

Start: 2010-10-31End: 2010-12-31Updated: 2015-08-17

Phase 3

DE-111 Against Timolol Ophthalmic Solution 0.5%

CompletedNCT01342094

Santen Pharmaceutical Co., Ltd.Ocular Hypertension, Open Angle Glaucoma

Start: 2011-05-31Updated: 2015-07-10